Literature DB >> 17222383

Costs of interventions for visual impairment.

Hugh R Taylor1, M Lynne Pezzullo, Sarah J Nesbitt, Jill E Keeffe.   

Abstract

PURPOSE: To quantify the economic costs of vision loss in Australia and assess the impact of a costed intervention package to prevent avoidable vision loss.
DESIGN: Existing Australian population-based data on prevalence and causes of visual impairment were used, and costs were calculated from published data for the five main causes of visual impairment.
METHODS: The cost of vision loss in Australia was determined from the weighted prevalence of visual impairment; unpublished data on the indirect costs of vision; and national databases on health care costs and other economic data. A costed intervention package was developed and its economic impact modeled. Outcome measures were total costs and savings from the interventions.
RESULTS: The intervention package would cost AU$188.8 million to implement in its first year but would bring a net return of AU$163.1 million in direct costs in the first year and an overall savings to the country of AU$911.1 million, a 4.8-fold return on investment.
CONCLUSIONS: Three-quarters of vision loss is avoidable, and many eye care interventions are cost effective. Even a developed economy cannot afford avoidable vision loss. Priority needs to be given to the prevention and treatment of avoidable vision loss.

Entities:  

Mesh:

Year:  2006        PMID: 17222383     DOI: 10.1016/j.ajo.2006.10.055

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  11 in total

1.  Does Visual Impairment Affect Social Ties in Late Life? Findings of a Multicenter Prospective Cohort Study in Germany.

Authors:  A Hajek; C Brettschneider; D Lühmann; M Eisele; S Mamone; B Wiese; S Weyerer; J Werle; M Pentzek; A Fuchs; J Stein; T Luck; H Bickel; D Weeg; K Heser; F Jessen; W Maier; M Scherer; S G Riedel-Heller; H-H König
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

Review 2.  An assessment of the health and economic burdens of glaucoma.

Authors:  Rohit Varma; Paul P Lee; Ivan Goldberg; Sameer Kotak
Journal:  Am J Ophthalmol       Date:  2011-10       Impact factor: 5.258

3.  [Methods for estimating personal costs of disease using retinal diseases as an example].

Authors:  G Porz; H P N Scholl; F G Holz; R P Finger
Journal:  Ophthalmologe       Date:  2010-03       Impact factor: 1.059

4.  Economic burden of glaucoma in Rivers State, Nigeria.

Authors:  Adedayo O Adio; Alfred A Onua
Journal:  Clin Ophthalmol       Date:  2012-12-05

5.  Prevalence and causes of visual impairment among Saudi adults attending primary health care centers in northern Saudi Arabia.

Authors:  Farhan Fayez Al-Shaaln; Marwan Abdurrahman Bakrman; Adel Mohammad Ibrahim; Abdullah Srour Aljoudi
Journal:  Ann Saudi Med       Date:  2011 Sep-Oct       Impact factor: 1.526

6.  Barriers to use of refractive services in Mozambique.

Authors:  Stephen Thompson; Kovin Naidoo; Carmen Gonzalez-Alvarez; Geoff Harris; Farai Chinanayi; James Loughman
Journal:  Optom Vis Sci       Date:  2015-01       Impact factor: 1.973

7.  The Cost of Blindness in the Republic of Ireland 2010-2020.

Authors:  D Green; G Ducorroy; E McElnea; A Naughton; A Skelly; C O'Neill; D Kenny; D Keegan
Journal:  J Ophthalmol       Date:  2016-02-15       Impact factor: 1.909

8.  Burden of visual impairment associated with eye diseases: exploratory survey of 298 Chinese patients.

Authors:  Xiaodong Guan; Mengyuan Fu; Fanghui Lin; Dawei Zhu; Daniel Vuillermin; Luwen Shi
Journal:  BMJ Open       Date:  2019-09-12       Impact factor: 2.692

Review 9.  The economic burden of blindness in Pakistan: a socio-economic and policy imperative for poverty reduction strategies.

Authors:  Haroon Awan; Sadia Mariam Malik; Niaz Ullah Khan
Journal:  Indian J Ophthalmol       Date:  2012 Sep-Oct       Impact factor: 1.848

Review 10.  What the comprehensive economics of blindness and visual impairment can help us understand.

Authors:  Kevin D Frick
Journal:  Indian J Ophthalmol       Date:  2012 Sep-Oct       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.